Small Molecules
13 December 2016
Cognition Therapeutics initiates US clinical testing of CT1812, a novel small molecule for the potential treatment of Alzheimer’s disease13 December 2016
Sage Therapeutics Announces Initiation of Phase 2 Clinical Development for SAGE-217 in Movement Disorders13 December 2016
RedHill Biopharma Announces Phase IIa 48-Week Final Results Further Supporting Potential of RHB-104 in Multiple Sclerosis12 December 2016
Cancer Targeted Technology Commences Phase I Clinical Trial of CTT1057, a Diagnostic Imaging Agent for Prostate Cancer12 December 2016
Eisai presents latest data on BACE inhibitor elenbecestat (E2609) at 9th Clinical Trials on Alzheimer’s Disease11 December 2016
Corcept Therapeutics Announces Encouraging Results of Phase 1/2 Trial of Mifepristone Plus Eribulin in Triple-Negative Breast Cancer9 December 2016
Start Phase 2b/3 study with filgotinib in ulcerative colitis8 December 2016
ContraVir’s Cyclophilin Inhibitor CRV431 Potently Inhibits Essential Pathway in Hepatitis B8 December 2016
Progenics Pharmaceuticals Announces First Patient Dosed in Phase 2/3 Clinical Trial of PSMA-Targeted PET/CT Imaging Agent PyL™8 December 2016
Arena Pharmaceuticals Completes Enrollment in Ralinepag Phase 2 Clinical Trial for Pulmonary Arterial Hypertension (PAH)8 December 2016
Lycera Announces Initiation of Phase 2 UPRISE Clinical Trial of LYC-30937-EC for Patients with Moderate Psoriasis8 December 2016
Voyager Therapeutics Announces Positive Interim Results from Phase 1b Trial of VY-AADC01 for Advanced Parkinson’s DiseaseNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
SubscribeNewsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
SubscribeFeatured reports